CytoMed Therapeutics to Explore Phase I Trial with Universiti Malaya
Ticker: GDTC · Form: 6-K · Filed: Dec 8, 2025 · CIK: 1873093
| Field | Detail |
|---|---|
| Company | Cytomed Therapeutics LTD (GDTC) |
| Form Type | 6-K |
| Filed Date | Dec 8, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, collaboration, biotech
TL;DR
CytoMed inks deal with Universiti Malaya for Phase I trial of its gamma delta T cell therapy.
AI Summary
On December 8, 2025, CytoMed Therapeutics Limited announced it has signed a Memorandum of Understanding with Universiti Malaya Medical Centre. This collaboration aims to explore the establishment of a multi-site, first-in-human Phase I clinical trial for CytoMed's patented donor-derived gamma delta T cell product candidate.
Why It Matters
This partnership marks a significant step in advancing CytoMed's novel cell therapy candidate towards clinical testing, potentially impacting future cancer treatment options.
Risk Assessment
Risk Level: medium — Early-stage clinical trial exploration carries inherent risks, including trial success, regulatory approval, and market adoption.
Key Players & Entities
- CytoMed Therapeutics Limited (company) — Registrant
- Universiti Malaya Medical Centre (company) — Partner for clinical trial exploration
- December 8, 2025 (date) — Date of press release and MOU signing
FAQ
What is the specific product candidate CytoMed Therapeutics is advancing?
CytoMed Therapeutics is advancing its patented donor-derived gamma delta T cell product candidate.
Which institution is CytoMed Therapeutics collaborating with for the clinical trial?
CytoMed Therapeutics is collaborating with Universiti Malaya Medical Centre.
What is the planned stage for the clinical trial?
The planned stage for the clinical trial is a multi-site, first-in-human Phase I trial.
When was the Memorandum of Understanding signed?
The Memorandum of Understanding was signed on December 8, 2025.
What is the primary purpose of the collaboration between CytoMed and Universiti Malaya Medical Centre?
The primary purpose is to explore the establishment of a multi-site, first-in-human Phase I clinical trial for CytoMed's gamma delta T cell product candidate.
Filing Stats: 285 words · 1 min read · ~1 pages · Grade level 15.6 · Accepted 2025-12-08 08:00:03
Filing Documents
- form6-k.htm (6-K) — 16KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-026530.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited Date: December 8, 2025 By: /s/ CHOO Chee Kong CHOO Chee Kong Director and Chairman